SARS-CoV-2 vaccination efficacy on hospitalisation and variants

Affiliations

¹ AP-HP, Bichat University Hospital, DMU PARABOL, Department of Anaesthesiology and Critical Care, Paris, France. Electronic address: sacha.rozencwajg@aphp.fr.
² AP-HP, Lariboisière-Saint-Louis Hospitals, Department of Anaesthesiology, Critical Care and Burn Centre, Paris, France; University of Paris, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France; University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
³ University Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de santé et des Pratiques médicales, F-59000, Lille, France.
⁴ University Hospital of Poitiers, Anaesthesiology, Critical Care and Perioperative Medicine Department, Poitiers, France; INSERM U-1070 Pharmacology of anti-infective agents, Poitiers, France.
⁵ Rouen University Hospital, Department of Anaesthesiology, Critical Care and Perioperative Medicine, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, F-76000, France.
⁶ University of Amiens-Picardie, Department of Anaesthesia and Critical Care, Amiens, France.

Editorial

Sacha Rozencwajg et al. Anaesth Crit Care Pain Med. 2021.

. 2021 Apr 23:100867.

doi: 10.1016/j.accpm.2021.100867. Online ahead of print.

¹ AP-HP, Bichat University Hospital, DMU PARABOL, Department of Anaesthesiology and Critical Care, Paris, France. Electronic address: sacha.rozencwajg@aphp.fr.
² AP-HP, Lariboisière-Saint-Louis Hospitals, Department of Anaesthesiology, Critical Care and Burn Centre, Paris, France; University of Paris, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France; University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
³ University Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de santé et des Pratiques médicales, F-59000, Lille, France.
⁴ University Hospital of Poitiers, Anaesthesiology, Critical Care and Perioperative Medicine Department, Poitiers, France; INSERM U-1070 Pharmacology of anti-infective agents, Poitiers, France.
⁵ Rouen University Hospital, Department of Anaesthesiology, Critical Care and Perioperative Medicine, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, F-76000, France.
⁶ University of Amiens-Picardie, Department of Anaesthesia and Critical Care, Amiens, France.

No abstract available

Figures

1. Peiffer-Smadja N, Rozencwajg S, Kherabi Y, et al. COVID-19 vaccines: A race against time. Anaesth Crit Care Pain Med 40:100848. https://doi.org/10.1016/j.accpm.2021.100848. - PMC - PubMed
1. Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371:1152-1153. https://doi.org/10.1126/science.abg6105. - PMC - PubMed
1. Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol 12:654165. https://doi.org/10.3389/fimmu.2021.654165. - PMC - PubMed
1. Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. https://doi.org/10.1016/j.cell.2021.03.036. - PMC - PubMed
1. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet 397:1351-1362. https://doi.org/10.1016/S0140-6736(21)00628-0. - PMC - PubMed